CHRS, US19249H1032

Coherus Oncology stock: Q3 plan prioritizes esophageal cancer

Published on 11/13/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology stock faces a sharper focus on esophageal cancer after its November 9 results. Cost cuts target lower quarterly cash burn.

Strategic shift and cost reset

Coherus is concentrating tagmokitug development on esophageal cancer and plans discussions with the U.S. Food and Drug Administration on an expedited path.
A planned workforce reduction of about 30% is intended to cut quarterly core cash burn by 6 million to 7 million US dollars.
LOQTORZI revenue rose year over year, while the company reported a quarterly loss from continuing operations.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology reported its third-quarter 2026 results on November 9 and announced a strategic shift toward esophageal cancer for tagmokitug. The company said in its company release that it would deprioritize other tagmokitug-toripalimab indications and seek regulatory alignment on a new study in previously treated esophageal cancer.

Coherus Oncology stock traded at 0.47 euros on Lang & Schwarz at 22:36 CET on Friday, November 13.

Esophageal cancer takes priority

The company plans to continue first-line and second-line studies in esophageal squamous cell carcinoma and second-line studies in esophageal adenocarcinoma. Across 22 treated and 13 evaluable second-line patients, the interim confirmed overall response rate was 33.3%, with a clinical benefit rate of 55.6%. The company said the figures were based on data available October 14.

Coherus plans to discuss the design of a new study and a proposed 700-milligram dose with the FDA. Management described second-line esophageal cancer as the initial focus for an expedited development path.

Revenue grows as losses continue

LOQTORZI revenue reached 14.0 million US dollars in the third quarter, up 25% from a year earlier and 3% from the second quarter. Net revenue from continuing operations was 14.3 million US dollars, compared with 11.6 million US dollars in the year-earlier quarter.

The company reported a 38.9 million US dollar net loss from continuing operations, or 0.25 US dollars per diluted share, versus a 44.5 million US dollar loss, or 0.38 US dollars per share, a year earlier. Non-GAAP net loss from continuing operations was 31.2 million US dollars, or 0.20 US dollars per share.

Smaller organization, lower cash burn

Coherus intends to reduce headcount by about 30% as it winds down transition services linked to its divested biosimilar business and completes a toripalimab manufacturing transfer. The company expects the changes to reduce quarterly core cash burn by 6 million to 7 million US dollars over the next two quarters and lower the LOQTORZI revenue needed to cover core costs to 25 million to 30 million US dollars per quarter.

Cash, cash equivalents and marketable securities totaled 83.6 million US dollars at September 30, 2026. The balance included amounts related to transition-service obligations.